Arkolith/Insider Trading/XLO/Form 4

Gilead Sciences, Inc.

10% OwnerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Feb 17, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 13, 2026Buy(P)3.7M$0.53$2.0M40.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001123292-26-000187) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML